Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Rhea-AI Summary

Tempus AI (NASDAQ:TEM) is highlighted within a broader cardiac AI diagnostics report. The piece outlines how hospital procurement is shifting toward AI platforms that combine regulatory clearances, commercial agreements, and economic evidence. It notes Tempus AI’s multi-specialty data and analytics footprint alongside growing AI cardiac imaging adoption.

AI-generated analysis. Not financial advice.

Positive

• Tempus AI 2025 revenue reported at approximately $1.2 billion
• 2026 revenue guidance of about $1.59 billion from Tempus AI
• Tempus AI projects around $65 million in 2026 adjusted EBITDA
• 2026 expected to be Tempus AI’s first year of positive adjusted profitability

Negative

• None.

Key Figures

AI cardiology market 2026: US$2.78 billion AI cardiology market 2034: US$14.22 billion Echocardiography market 2030: US$2.64 billion +5 more

8 metrics

AI cardiology market 2026 US$2.78 billion Projected size of AI in cardiology market in 2026

AI cardiology market 2034 US$14.22 billion Projected size by 2034 with 22.6% compound annual growth rate

Echocardiography market 2030 US$2.64 billion Forecast size of echocardiography segment by 2030

Portable ultrasound 2026 US$2.79 billion Estimated global portable ultrasound market value in 2026

Cardiovascular patients in China 330 million Estimated cardiovascular disease patient population cited for China

Tempus 2025 revenue US$1.2 billion Tempus AI full-year 2025 revenue as AI platform peer

Tempus 2026 guidance US$1.59 billion revenue, US$65 million adj. EBITDA Tempus AI 2026 outlook indicating first positive adjusted profitability

RadNet AI recurring revenue US$30 million Projected annualized recurring AI revenue from RadNet–Gleamer combination in 2026

Market Reality Check

Price: $54.17 Vol: Volume 466,876 is below t...

low vol

$54.17 Last Close

Volume Volume 466,876 is below the 20-day average of 925,239, suggesting limited pre-news activity. low

Technical Shares at 54.17 trade below the 200-day MA of 69.42 and well under the 85.84 52-week high, though above the 50.76 52-week low.

Peers on Argus

RDNT was up 3.4% while close peers showed mixed, modest moves: GH -0.31%, SHC +0...

RDNT was up 3.4% while close peers showed mixed, modest moves: GH -0.31%, SHC +0.33%, CRL -1.49%, RVTY +1.65%, WGS +2.08%. This points to stock-specific dynamics rather than a broad sector swing.

Previous AI Reports

5 past events · Latest: Mar 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	AI portfolio launch	Positive	-1.7%	DeepHealth unveiled broad native clinical AI suite and Gleamer acquisition at ECR 2026.
Nov 30	AI platform expansion	Positive	-3.4%	Expanded imaging informatics and clinical AI solutions showcased at RSNA 2025.
Nov 17	AI study results	Positive	+2.8%	Nature Health ASSURE study showed higher cancer detection from AI screening workflow.
Nov 12	GE AI collaboration	Positive	-1.3%	DeepHealth and GE HealthCare expanded strategic collaboration across imaging modalities.
Jul 09	AI program adoption	Positive	+4.2%	Southern California medical groups added RadNet’s EBCD AI breast program to benefits.

Pattern Detected

AI-focused announcements have generally been positive fundamentally but often met with muted or negative next-day price reactions, with only some events producing clear upside moves.

Recent Company History

Across the last five AI-tagged announcements, RadNet’s DeepHealth unit has highlighted expanding AI portfolios, large real‑world breast cancer screening data, and collaborations with GE HealthCare, plus payor adoption of its EBCD program. Despite strong clinical and adoption metrics, next‑day moves were mixed: some key unveilings at ECR 2026 and RSNA 2025 saw share price declines, while the Nature Health study and Southern California health-plan adoption produced gains. Today’s article again situates RadNet as a scale AI imaging peer in a rapidly growing cardiac AI market.

Historical Comparison

+0.1% avg move · Past AI-focused headlines moved RDNT about 0.1% on average the next day, with several strong clinica...

AI

+0.1%

Average Historical Move AI

Past AI-focused headlines moved RDNT about 0.1% on average the next day, with several strong clinical and partnership updates still seeing muted or negative reactions.

AI news has progressed from payor adoption of EBCD to large real‑world validation, then to broad portfolio launches and deepening GE HealthCare collaborations, underscoring RadNet’s strategy of scaling AI across modalities.

Market Pulse Summary

This announcement situates RadNet alongside leading cardiac and imaging AI platforms, noting project...

Analysis

This announcement situates RadNet alongside leading cardiac and imaging AI platforms, noting projected recurring AI revenue of about $30 million from its Gleamer acquisition and DeepHealth portfolio. It underscores a rapidly expanding AI cardiology market, where hospitals increasingly demand economic proof and recurring-revenue deployment models. In context of prior AI launches, collaborations, and real‑world validation studies, investors may watch how RadNet converts these capabilities into broader deployments and sustained Digital Health growth.

Key Terms

echocardiography, magnetic resonance imaging, National Medical Products Administration, compound annual growth rate, +1 more

5 terms

echocardiography medical

"Echocardiography alone — the most widely used cardiac imaging modality in the world —"

An echocardiography is a noninvasive test that uses sound waves to create moving images of the heart, showing its size, pumping strength and how the valves work—think of it as an ultrasound camera for the heart. Investors care because these images provide objective measures used to diagnose heart disease, guide treatment decisions, support clinical-trial endpoints and drive demand for medical devices and services, which affects revenue and reimbursement outlooks.

magnetic resonance imaging medical

"equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems"

Magnetic resonance imaging (MRI) is a medical scan that uses strong magnets and radio waves to make detailed pictures of the inside of the body without X-rays or surgery. For investors, MRI matters because the machines, software, maintenance, and scan services represent steady capital spending and revenue streams for equipment makers, hospitals and imaging centers; advances or wider adoption can change market size, pricing power and competitive dynamics much like a camera upgrade transforms picture quality and demand.

National Medical Products Administration regulatory

"submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA)"

The National Medical Products Administration is the government agency responsible for reviewing, approving and supervising drugs, vaccines, medical devices and related products. Think of it as the country’s gatekeeper for medical products: its decisions determine whether a product can be sold, how quickly it reaches patients and what safety or labeling requirements apply, so its rulings directly affect a company’s sales prospects, regulatory risk and investor valuation.

compound annual growth rate financial

"to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6%"

The compound annual growth rate (CAGR) shows how much an investment or value has grown, on average, each year over a specific period. It considers the effect of growth that compounds or builds upon itself, similar to how interest accumulates in a savings account. Investors use CAGR to compare different investments’ long-term performance and to understand how steady or consistent their growth has been over time.

adjusted EBITDA financial

"issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

AI-generated analysis. Not financial advice.

Issued on behalf of Ventripoint Diagnostics Ltd.

A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globally

NEW YORK, May 19, 2026 /PRNewswire/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recurring revenue, and which cannot. The companies winning right now are the ones stacking regulatory clearances, commercial partnerships, and reimbursement-friendly clinical evidence at the same time.

Industry forecasts help frame the prize at stake. The artificial intelligence in cardiology market has been projected to grow from approximately US$2.78 billion in 2026 to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6% over the period.[1] Echocardiography alone — the most widely used cardiac imaging modality in the world — is forecast to expand to US$2.64 billion by 2030 as health systems demand cardiac platforms that prove economic value alongside clinical accuracy.[2]

Read the full report of Ventripoint here: USA News Group Ventrpoint Coverage

Portable ultrasound, valued at roughly US$2.79 billion in 2026, is pushing cardiac assessment beyond the imaging lab and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts.[3]

Inside that environment, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) has spent the first half of 2026 stringing together exactly the kinds of validation events that the new procurement environment rewards.

The Toronto-headquartered company applies proprietary Knowledge Based Reconstruction technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor.

A Regulatory Submission Into the World's Largest Cardiac Disease Population

On April 28, 2026, Ventripoint announced that its strategic partner Lishman Global Inc. had formally submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for approval.[4] The filing is the principal regulatory gating event for VMS+ access to the Chinese cardiology market, and according to the Company, Lishman Global qualified for the NMPA's "green channel" pathway, an expedited review process designed for innovative medical technologies that address significant clinical needs.[4]

The scale of the opportunity is difficult to overstate. The Company has cited an estimated 330 million cardiovascular disease patients in China, with cardiovascular disease the leading cause of mortality in the country.[4]

Echocardiography is already the most widely used cardiac imaging modality in China because of its cost-effectiveness, portability, and scalability across both urban and rural healthcare settings.[4] What the market has been short on, in Ventripoint's framing, is the kind of AI-driven analytic layer that produces consistent, MRI-equivalent volumetric measurements from those existing ultrasound exams — particularly given variability in image interpretation across operators and limited access to advanced modalities like MRI in many parts of the country.

"China is one of the most important cardiac care markets in the world," said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, in the announcement. "With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."[4] Paul Gibson, Chief Technology Officer of Lishman Global, added that qualification for the NMPA's green channel "underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."[4]

Read the full report of Ventripoint here: USA News Group Ventrpoint Coverage

Bringing AI Cardiac Imaging Into a Padua-Based European Congress

Six days after the NMPA submission was announced, Ventripoint disclosed plans to exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), held May 12–16, 2026 in Padua, Italy.[5] Founded in 1963, AEPC is described as the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries.[5]

The 2026 meeting was hosted by the University of Padova and featured a scientific program centred on advanced cardiovascular imaging and artificial intelligence — a fit, the Company argued, for what VMS+ is designed to deliver.[5]

A central focus of Ventripoint's booth at AEPC was the use of VMS+ to support evolution of cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and which affirm echocardiography as the key modality for longitudinal assessment of ventricular function.[5] The latest release, VMS+ 4.0, was purpose-built around the workflow needs of clinicians, the Company has said, streamlining the time required to generate assessments and making volumetric cardiac analysis accessible at the point of care.[5]

"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," MacNaught said in the AEPC announcement. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI — giving clinicians the confidence they need to manage their patients at every stage of life."[5]

A Wider Pattern of Validation Events Through Spring 2026

The NMPA submission and AEPC exhibition are the two most recent links in a chain of events the Company has been building since the start of the year. Earlier in spring 2026, Ventripoint announced its Edison Award recognition, signed a commercial agreement with LG Consulting Solutions to support deployment of VMS+ across Northern California hospital systems, and announced a partnership delivering AI 3D heart mapping into Indigenous community settings through a Nisg̱a'a partnership.[6]

Considered together, those steps describe a small-cap AI medtech company simultaneously stacking validation across regulatory, commercial, and clinical fronts at the exact moment the broader hospital procurement environment is reorganizing around AI clinical solutions.[6]

The LG Consulting Solutions agreement is structured precisely to address the financial proof requirement that has come to dominate hospital adoption decisions. Under the agreement, LG Consulting provides economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology.[6]

In other words, the commercial framework on the ground in Northern California is designed to deliver department-level economic justification — which is exactly what hospital procurement is currently demanding before they sign.

How Ventripoint Sits Inside a Reshaping Cardiac AI Field

Ventripoint is far from the only public company chasing the AI cardiac imaging opportunity. Several larger names have moved aggressively across the past year — and the procurement environment for AI medtech is reshaping in real time as a result.

Butterfly Network, Inc. (NYSE: BFLY) is one of the highest-profile names in handheld ultrasound. The Company has continued to expand integrations between its iQ family of probes and third-party AI cardiac applications, including the August 2025 announcement integrating Bordeaux-based DESKi's HeartFocus cardiac examination software into Butterfly's handheld devices — software that received FDA clearance in April 2025 and that allows healthcare professionals with minimal training to capture complete echocardiographic views.[7] Butterfly's strategy of partnering with AI cardiac software vendors places it in a structurally adjacent — but distinct — segment of the cardiac AI market from a knowledge-based reconstruction platform like Ventripoint's VMS+.

Tempus AI, Inc. (NASDAQ: TEM) has been one of the cardiology AI sector's most-watched commercial stories. Tempus generated $1.2 billion in revenue for full-year 2025 and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA — projecting its first year of positive adjusted profitability.[1] Tempus's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care — a substantially broader footprint than a pure-play cardiac imaging company, but one that frames the institutional investor appetite for AI medical platforms more generally. 

RadNet, Inc. (NASDAQ: RDNT) has built one of the larger imaging-services-plus-AI businesses through its DeepHealth subsidiary. RadNet's recent acquisition of Gleamer — whose products are deployed in over 2,000 facilities across 30 countries — uniquely positions DeepHealth to expand its impact across routine imaging and accelerate the delivery of automated diagnostics, with the combined entity projected to generate approximately $30 million in annualized recurring AI revenue in 2026.[1] RadNet's scale on the imaging-services side gives it a different kind of moat than a pure software vendor — but the strategic message about AI moving from pilot to recurring revenue is the same one playing out across the sector.

GE HealthCare Technologies Inc. (NASDAQ: GEHC) brings the perspective of one of the world's largest installed bases of cardiac imaging equipment. GE HealthCare has been advancing its own cardiac imaging capabilities through AI-powered reconstruction technologies — including AIR Recon DL and Sonic DL — designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.[1]

The fact that the largest incumbent in the space is investing aggressively in AI-augmented cardiac imaging is, if anything, supportive of the thesis that AI-enhanced echocardiography platforms like Ventripoint's are arriving into a market actively being reorganized around AI-driven clinical workflows. 

Across all four comparables, the same pattern shows up: hospital systems are demanding economic proof, AI cardiac imaging is shifting from pilot to recurring revenue, and AI-augmented echocardiography is increasingly viewed as the most leverageable cardiac modality given its existing scale, portability, and cost profile.

What Comes Next

Ventripoint's near-term catalysts are reasonably visible. The NMPA review process for VMS+ 4.0 in China is now underway, and the Company has said it will provide further updates as the review process progresses.[4] On the commercial side, the LG Consulting Solutions deployment partnership in Northern California is set up to convert clinical evidence into hospital-level economic justification.[6] On the European side, the AEPC exhibition in Padua delivered direct engagement with the largest concentration of paediatric and congenital cardiologists in Europe — a clinical community uniquely well-suited to longitudinal echocardiography-driven follow-up of complex patients.[5]

The Company's stated 2026 priority is accelerating the integration of VMS+ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients.[5]

For investors tracking the cardiac AI sector, the Company offers a small-cap exposure to a corner of the AI medtech market where the procurement environment, the regulatory environment, and the clinical evidence base have all moved into alignment within the past six months. Whether that alignment translates into accelerating commercial momentum will be measured one deployment, one NMPA decision, and one congress at a time across the back half of 2026.

Read the full report of Ventripoint here: USA News Group Ventrpoint Coverage

CONTACT INFORMATION
USA News Group
info@USANewsgroup.com
604-265-2873

Article Sources

[1] https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 

[2] https://www.marketresearch.com/Business-Research-Company-v4006/Cardiac-AI-Monitoring-Diagnostics-Global-44014609/ 

[3] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report 

[4] https://finance.yahoo.com/sectors/healthcare/articles/ventripoints-vms-tm-4-0-120000052.html 

[5] https://finance.yahoo.com/sectors/healthcare/articles/ventripoint-exhibit-59th-annual-meeting-132316747.html 

[6] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html 

[7] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report

DISCLAIMER NOTICE

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.html

SOURCE USA News Group

FAQ

What 2025 revenue did Tempus AI (NASDAQ:TEM) report in this cardiac AI sector update?

Tempus AI is described as generating about $1.2 billion in 2025 revenue. According to Tempus AI, this revenue comes from its platform integrating genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care.

What 2026 financial guidance did Tempus AI (TEM) provide for revenue and adjusted EBITDA?

Tempus AI issued 2026 guidance of roughly $1.59 billion in revenue and about $65 million in adjusted EBITDA. According to Tempus AI, this outlook would mark its first year of positive adjusted profitability across its multi-specialty AI medical platform.

How does Tempus AI’s business compare to pure-play cardiac imaging companies in 2026?

Tempus AI operates a broad AI medical platform spanning oncology, cardiology, and neuropsychiatry. According to Tempus AI, this footprint differs from pure-play cardiac imaging firms, framing wider institutional investor interest in large-scale AI medical data and analytics platforms.

What role does Tempus AI play in the growing AI cardiology market?

Tempus AI is presented as one of the sector’s most-watched commercial stories. According to Tempus AI, its platform integrates genomic and clinical data with AI insights, positioning the company within the expanding adoption of AI tools in cardiology and related specialties.

Why might investors track Tempus AI (TEM) alongside smaller cardiac AI companies?

Investors may use Tempus AI as a large-platform benchmark for AI medicine. According to Tempus AI figures, its billion-dollar revenue scale and positive adjusted profitability guidance help contextualize valuation and growth expectations for smaller, more focused cardiac AI imaging companies.

Does Tempus AI’s guidance indicate a shift in its profitability profile for 2026?

Yes. Tempus AI’s 2026 outlook includes approximately $65 million in adjusted EBITDA. According to Tempus AI, this level of adjusted earnings would represent its first projected year of positive adjusted profitability across its AI-enabled clinical data platform.